drugset / Trial / NCT05020028

Cannabidiol (CBD) in Pain Reduction for Knee Osteoarthritis

NCT05020028

Phase 2/3 Recruiting 100 enrolled NYU Langone Health Orcosa Inc. · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to see if cannabidiol (CBD) orally dissolving tablets (ODTs) can lessen pain, improve function, and improve patient satisfaction in cases of knee osteoarthritis. CBD comes from the cannabis plant and is non-psychoactive (i.e. does not produce a 'high' or altered mental state) as compared to tetrahydrocannabinol (THC), another compound found in cannabis. Researchers are studying different forms of CBD for potential use in treating pain, inflammation, and illnesses.

Timeline

Start
2022-06-22
Primary completion
2027-09
Completion
2027-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Cannabidiol Other / unclassified 50 mg Oral

Indications